EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pyxis Oncology's Enterprise Value is $163.05 Mil.
Pyxis Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-82.20 Mil. Therefore, Pyxis Oncology's EV-to-EBIT for today is -1.98.
The historical rank and industry rank for Pyxis Oncology's EV-to-EBIT or its related term are showing as below:
PYXS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -2307.51 Med: 0 Max: 5736.93
Current: -1.98
During the past 5 years, the highest EV-to-EBIT of Pyxis Oncology was 5736.93. The lowest was -2307.51. And the median was 0.00.
PYXS's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs PYXS: -1.98
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Pyxis Oncology's Enterprise Value for the quarter that ended in Dec. 2023 was $-17.41 Mil.
Pyxis Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-82.20 Mil. Pyxis Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 472.16%.
Pyxis Oncology EV-to-EBIT Historical Data
The historical data trend for Pyxis Oncology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pyxis Oncology's EV-to-EBIT
For the Biotechnology subindustry, Pyxis Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's EV-to-EBIT falls into.
Pyxis Oncology EV-to-EBIT Calculation
Pyxis Oncology's EV-to-EBIT for today is calculated as:
Pyxis Oncology's current Enterprise Value is $163.05 Mil.
Pyxis Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology (NAS:PYXS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pyxis Oncology's Enterprise Value for the quarter that ended in Dec. 2023 was $-17.41 Mil.
Pyxis Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology (Pyxis Oncology) Business Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your 